Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective NIS to Generate Real-World-Data on Effectiveness and Safety of First-line Therapy With Chemotherapy Combined With Durvalumab Followed by Maintenance Therapy With Durvalumab or Durvalumab + Olaparib in Endometrial Cancer

NCT06890273 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06890273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06890273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective NIS to Generate Real-World-Data on Effectiveness and Safety of First-line Therapy With Chemotherapy Combined With Durvalumab Followed by Maintenance Therapy With Durvalumab or Durvalumab + Olaparib in Endometrial Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
May 20, 2025
Completion date
March 31, 2029
Enrollment
150 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer